The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 701–800 of 1,011
Org, E., Mehrabian, M., & Lusis, A. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.035 · Cited by 85
Chen, M., Hui, S., Lang, H., Zhou, M., Zhang, Y., Kang, C., Zeng, X., Zhang, Q., Yi, L., & Mi, M. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800612 · Cited by 85
Wang, L., Wu, Y., Zhuang, L., Chen, X., Min, H., Song, S., Liang, Q., Li, A., & Gao, Q. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218490 · Cited by 87
Ye, Z., Xu, Y., & Liu, Y. (2021) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2021.05.001 · Cited by 86
Gut microbiota, fatty liver disease, and hepatocellular carcinoma
Chu, H., Williams, B., & Schnabl, B. (2018) · Liver Research · doi:10.1016/j.livres.2017.11.005 · Cited by 84
Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases
Hyun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179139 · Cited by 87
Li, R., & Zhu, S. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100859 · Cited by 85
Zhao, K., Wu, X., Han, G., Sun, L., Zheng, C., Hou, H., Xu, B. B., El-Bahy, Z. M., Qian, C., Kallel, M., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128588 · Cited by 84
Correa‐Fiz, F., Fraile, L. J., & Aragón, V. (2016) · BMC Genomics · doi:10.1186/s12864-016-2700-8 · Cited by 88
Linking intestinal homeostasis and liver disease
Schnabl, B. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835ff948 · Cited by 83
McPhee, J. B., & Schertzer, J. D. (2015) · Clinical Science · doi:10.1042/cs20150431 · Cited by 86
Ferreira‐Pêgo, C., Babió, N., Bes‐Rastrollo, M., Corella, D., Estruch, R., Ros, E., Fitó, M., Serra‐Majem, L., Arós, F., Fiol, M., et al. (2016) · Journal of Nutrition · doi:10.3945/jn.116.230367 · Cited by 88
Khalyfa, A., Ericsson, A. C., Qiao, Z., Almendros, I., Farré, R., & Gozal, D. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103208 · Cited by 85
Ishikawa, H., Takaki, A., Tsuzaki, R., Yasunaka, T., KOIKE, K. A., Shimomura, Y., Seki, H., Matsushita, H., Miyake, Y., Ikeda, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100627 · Cited by 83
Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD
Fuchs, C. D., Claudel, T., & Trauner, M. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.08.001 · Cited by 85
Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82
Zhang, H.-F., Shi, L., Song, G., Cai, Z.-G., Wang, C., & An, R.-J. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.12.043 · Cited by 82
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 87
Cardiolipotoxicity, Inflammation, and Arrhythmias: Role for Interleukin-6 Molecular Mechanisms
Alì, A., Boutjdir, M., & Aromolaran, A. S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01866 · Cited by 86
The heart-gut axis: new target for atherosclerosis and congestive heart failure therapy
Forkosh, E., & Ilan, Y. (2019) · Open Heart · doi:10.1136/openhrt-2018-000993 · Cited by 86
Gestational Diabetes Is Uniquely Associated With Altered Early Seeding of the Infant Gut Microbiota
Soderborg, T. K., Carpenter, C. M., Janssen, R. C., Weir, T. L., Robertson, C. E., Ir, D., Young, B. E., Krebs, N. F., Hernandez, T. L., Barbour, L. A., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.603021 · Cited by 82
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 87
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 86
The interplay between the intestinal microbiota and the immune system
Lei, Y. M., Nair, L., & Alegre, M. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.10.008 · Cited by 87
Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
Brandl, K., & Schnabl, B. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1057122 · Cited by 82
Jump, D. Β., Depner, C. M., Tripathy, S., & Lytle, K. A. (2015) · Advances in Nutrition · doi:10.3945/an.115.009423 · Cited by 84
du Plessis, J., Korf, H., van Pelt, J. F., Windmolders, P., Elst, I. V., Verrijken, A., Hubens, G., Gaal, L. V., Cassiman, D. M., Nevens, F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166048 · Cited by 83
Shaping of Intestinal Microbiota in Nlrp6- and Rag2-Deficient Mice Depends on Community Structure
Gálvez, E. J. C., Iljazovic, A., Gronow, A., Flavell, R., & Strowig, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.027 · Cited by 81
Self-citationAlshawsh, M. A., Alsalahi, A., Alshehade, S. A., Saghir, S. A. M., Ahmeda, A. F., Al Zarzour, R. H., & Mahmoud, A. M. (2022) · Molecules · doi:10.3390/molecules27030858 · Cited by 81
He, X., Ji, G., Jia, W. P., & Li, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030300 · Cited by 82
Estrogens and female liver health
Chen, K. L., & Madak‐Erdogan, Z. (2017) · Steroids · doi:10.1016/j.steroids.2017.10.015 · Cited by 81
Chen, J., He, S., Fang, L., Wang, B., Bai, S., Xie, J., Zhou, C., Wang, W., & Xie, P. (2020) · Aging · doi:10.18632/aging.102775 · Cited by 82
Xu, L., Chen, Y., Nagashimada, M., Ni, Y., Zhuge, F., Chen, G., Li, H., Pan, T., Yamashita, T., Mukaida, N., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154914 · Cited by 81
Martemucci, G., Fracchiolla, G., Muraglia, M., Tardugno, R., Dibenedetto, R. S., & D‘Alessandro, A. G. (2023) · Antioxidants · doi:10.3390/antiox12122091 · Cited by 89
Zhou, L., Qiu, X., Meng, Z., Liu, T., Chen, Z., Zhang, P., Kuang, H., Pan, T., Lu, Y., Qi, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1866 · Cited by 85
Regulatory mechanism of HIF-1α and its role in liver diseases: a narrative review
Chu, Q., Gu, X., Zheng, Q., & Zhu, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4222 · Cited by 84
Sun, Q., Gao, W., Loughran, P., Shapiro, R., Fan, J., Billiar, T. R., & Scott, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426791 · Cited by 80
Caspases in metabolic disease and their therapeutic potential
Wilson, C. H., & Kumar, S. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0111-x · Cited by 84
Intrahepatic microbes govern liver immunity by programming NKT cells
Leinwand, J., Paul, B., Chen, R., Xu, F., Sierra, M. A., Paluru, M. M. R., Nanduri, S., Hirsch, C. A., Shadaloey, S. A. A., Yang, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151725 · Cited by 83
Protective effect of genistein on nonalcoholic fatty liver disease (NAFLD)
Xin, X., Chen, C., Hu, Y., & Feng, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109047 · Cited by 78
The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology
Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 79
Aron‐Wisnewsky, J., & Clément, K. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0454-9 · Cited by 81
Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification
Dyson, J. K., McPherson, S., & Anstee, Q. M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201620 · Cited by 78
Lü, M., Tang, Y., Li, M., Yang, P., Liu, Z., Yuan, J., & Zheng, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138078 · Cited by 78
Gut microbiota and non-alcoholic fatty liver disease
Gkolfakis, P., Dimitriadis, G., & Τriantafyllou, Κ. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(15)60026-1 · Cited by 80
Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance
Revelo, X. S., Ghazarian, M., Chng, M. H. Y., Luck, H., Kim, J. H., Zeng, K., Shi, S. Y., Tsai, S. J., Lei, H., Kenkel, J. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.024 · Cited by 83
The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation
Schrumpf, E., Kummen, M., Valestrand, L., Greiner, T. U., Holm, K., Arulampalam, V., Reims, H. M., Baines, J. F., Bäckhed, F., Karlsen, T. H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.020 · Cited by 80
A complex microworld in the gut: Gut microbiota and cardiovascular disease connectivity
Howitt, M. R., & Garrett, W. S. (2012) · Nature Medicine · doi:10.1038/nm.2895 · Cited by 78
Bibliometric analysis of research on the role of intestinal microbiota in obesity
Yao, H., Wan, J., Wang, C., Li, L., Wang, J., Li, Y., Huang, W., Zeng, J., Wang, Q., & Yuan, C. (2018) · PeerJ · doi:10.7717/peerj.5091 · Cited by 78
Yang, X., Mo, W., Zheng, C., Li, W., Tang, J., & Wu, X. (2020) · Food & Function · doi:10.1039/d0fo00178c · Cited by 76
Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease
Samarraie, A. A., Pichette, M., & Rousseau, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065420 · Cited by 78
Role of caspase-1 in regulation of triglyceride metabolism
Kotas, M. E., Jurczak, M. J., Annicelli, C., Gillum, M. P., Cline, G. W., Shulman, G. I., & Medzhitov, R. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301996110 · Cited by 76
Self-citationTargeting gut flora to prevent progression of hepatocellular carcinoma
Darnaud, M., Faivre, J., & Moniaux, N. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.019 · Cited by 76
Host-Microbiome Interactions in Alcoholic Liver Disease
Chen, P., & Schnabl, B. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.3.237 · Cited by 76
Helicobacter pyloriinfection is not associated with nonalcoholic fatty liver disease
Baeg, M. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2592 · Cited by 76
Small Intestinal Bacterial Overgrowth Is Associated with Non- Alcoholic Fatty Liver Disease
Fialho, A. B. C., Fialho, A., Thota, P. N., McCullough, A. J., & Shen, B. (2016) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.252.iwg · Cited by 76
Adipose type I interferon signalling protects against metabolic dysfunction
Wieser, V. E., Adolph, T. E., Grander, C., Grabherr, F., Enrich, B., Moser, P. L., Moschen, A. R., Kaser, S., & Tilg, H. (2016) · Gut · doi:10.1136/gutjnl-2016-313155 · Cited by 78
Inflammatory disease caused by intestinal pathobionts
Zechner, E. L. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.01.011 · Cited by 76
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. Z. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 76
Self-citationLeng, W., Wu, M., Pan, H., Lei, X., Chen, L., Wu, Q., Ouyang, X., & Liang, Z. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.03 · Cited by 75
Bhattacharjee, A., Burr, A. B. P., Overacre-Delgoffe, A. E., Tometich, J. T., Yang, D., Huckestein, B. R., Linehan, J. L., Spencer, S. P., Hall, J. A., Harrison, O. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.005 · Cited by 75
Lipid regulation of NLRP3 inflammasome activity through organelle stress
Liang, J. J., Fraser, I. D. C., & Bryant, C. E. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.07.005 · Cited by 79
Mitochondrial DNA induces nucleus pulposus cell pyroptosis via the TLR9-NF-κB-NLRP3 axis
Lu, P., Zheng, H., Meng, H., Liu, C., Duan, L., Zhang, J., Zhang, Z., Gao, J., Zhang, Y., & Sun, T. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04266-5 · Cited by 84
Current status of inflammasome blockers as anti-inflammatory drugs
López‐Castejón, G., & Pelegrı́n, P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.690032 · Cited by 77
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 79
Zhang, Z., Zhang, X., Wu, B., Yin, J., Yu, Y., & Yang, L. (2016) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2016.05.011 · Cited by 75
Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases
Ignácio, A., Morales, C., Câmara, N. O. S., & Almeida, R. R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00054 · Cited by 75
Potential role of phytochemicals in metabolic syndrome prevention and therapy
Francini, F.-P., Spinella, P., & Calò, L. A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s214550 · Cited by 74
Wu, G., Shi, Y., Han, L., Feng, C., Ge, Y., Yu, Y., Xue Ming, T. A. N. G., Cheng, X., Sun, J., & Le, G. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02965 · Cited by 74
Zou, Y., Chen, Z., Sun, C., Yang, D. K., Zhou, Z., Peng, X., Zheng, L., & Tang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010940 · Cited by 76
The Lactobacillus as a Probiotic: Focusing on Liver Diseases
Jeong, J., Park, H., Cha, M. G., Park, E., Won, S., Ganesan, R., Gupta, H., Gebru, Y. A., Sharma, S. P., Lee, S. B., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10020288 · Cited by 75
Local and systemic effects of microbiome‐derived metabolites
Spivak, I., Fluhr, L., & Elinav, E. (2022) · EMBO Reports · doi:10.15252/embr.202255664 · Cited by 75
Self-citationPyroptosis in development, inflammation and disease
Pan, Y., Cai, W., Huang, J., Cheng, A., Wang, M., Yin, Z., & Jia, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991044 · Cited by 74
Shi, R., Jin, Y., Fan, H., Xiao, C., Wang, D., Xia, B., Zhao, Z., Zhao, B., Dai, X., & Liu, X. (2023) · Food & Function · doi:10.1039/d2fo03411e · Cited by 74
The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
Mehal, W. Z. (2014) · Digestive Diseases · doi:10.1159/000360495 · Cited by 77
Self-citationMcCaughey, L. C., Grinter, R., Josts, I., Roszak, A. W., Waløen, K. I., Cogdell, R. J., Milner, J. J., Evans, T. J., Kelly, S. M., Tucker, N. P., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003898 · Cited by 74
Ohtani, N. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0457-1 · Cited by 76
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease
Chen, G., Ni, Y., Nagata, N., Xu, L., & Ota, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091379 · Cited by 75
Non-alcoholic fatty liver disease in 2016
Townsend, S. A., & Newsome, P. N. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw031 · Cited by 76
Xiao, J., Wang, F., Liong, E. C., So, K., & Tipoe, G. L. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.09.151 · Cited by 73
Kim, E. K., Lee, K.-A., Hyeon, D. Y., Kyung, M., Jun, K.-Y., Seo, S. H., Hwang, D., Kwon, Y., & Lee, W. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.01.025 · Cited by 73
Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
Malnick, S. D. H., Alin, P., Somin, M., & Neuman, M. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416226 · Cited by 78
Fizanne, L., Villard, A., Benabbou, N., Recoquillon, S., Soleti, R., Delage, E., Wertheimer, M., Vidal‐Gómez, X., Oullier, T., Chaffron, S., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12303 · Cited by 73
Kopec, A. K., Joshi, N., Towery, K., Kassel, K. M., Sullivan, B. P., Flick, M. J., & Luyendyk, J. P. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218545 · Cited by 73
Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases
Guo, B., & Li, Z. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00242 · Cited by 73
Role of Inflammasomes in Intestinal Inflammation and Crohnʼs Disease
Opipari, A. W., & Franchi, L. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000230 · Cited by 75
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 79
Douhara, A., Moriya, K., Yoshiji, H., Noguchi, R., Namisaki, T., Kitade, M., Kaji, K., Aihara, Y., Nishimura, N., Takeda, K., et al. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2995 · Cited by 73
Lambert, J. E., Parnell, J. A., Eksteen, B., Raman, M., Bomhof, M. R., Rioux, K. P., Madsen, K. L., & Reimer, R. A. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0400-5 · Cited by 73
He, K., Zhu, X., Liu, Y., Miao, C., Wang, T., Li, P., Zhao, L., Chen, Y., Gong, J., Cai, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17489 · Cited by 73
Vujkovic-Cvijin, I., Rutishauser, R. L., Pao, M., Hunt, P. W., Lynch, S. V., McCune, J. M., & Somsouk, M. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1334034 · Cited by 74
Chen, C., Liu, Q., Liu, L., Hu, Y., & Feng, Q. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700483 · Cited by 78
Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either
Hartmann, P., Chu, H., Duan, Y., & Schnabl, B. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00370.2018 · Cited by 74
Mitochondrial adaptation in steatotic mice
Einer, C., Hohenester, S., Wimmer, R., Wottke, L., Artmann, R., Schulz, S., Gosmann, C., Simmons, A., Leitzinger, C., Eberhagen, C., et al. (2018) · Mitochondrion · doi:10.1016/j.mito.2017.08.015 · Cited by 72
Arab, J. P., Arrese, M. A., & Shah, V. H. (2019) · Hepatology Research · doi:10.1111/hepr.13473 · Cited by 76
Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes
Scapaticci, S., D’Adamo, E., Mohn, A., Chiarelli, F., & Giannini, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.639548 · Cited by 76
Karlas, T., Wiegand, J., & Berg, T. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.02.002 · Cited by 74
Blasco‐Baqué, V., Coupé, B., Fabre, A., Handgraaf, S., Gourdy, P., Arnal, J., Courtney, M., Schuster, C., Guardiola, B., Tercé, F., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4209-3 · Cited by 73
Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers
Gingold, J. A., Zhu, D., Lee, D., Kaseb, A. O., & Chen, J. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.02.006 · Cited by 72
Cellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Development
Ignat, S.-R., Dinescu, S., Hermenean, A. O., & Costache, M. (2020) · Cells · doi:10.3390/cells9020461 · Cited by 75
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
